ECCA
 WHO
 CLS 
LPR
Web Counter:
46731 visitors
00 days left
 to the Congress
Scientific Programme

Scientific Programme at the Glance can be downloaded here.
Please see also Detailed Scientific Programme bellow.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 


Detailed Scientific Programme

 

Thursday, May 1, 2008

09:00 – 15:30   Colposcopy Course
    Lukáš Rob, Charles W. E. Redman, Carl Chow, Joseph Jordan, Marek Pluta
     
  Chair: Vladimír Vonka
     
16:00 – 17:00   Neoplastic Diseases Caused by Viruses
    Ivan Hirsch
     
17:00 – 18:00   The History of Papillomavirus Research
    Stina Syrjanen
     
18:00 – 20:00   WELCOME COCKTAIL

 

Friday, May 2, 2008

    Chair: Marek Pluta
     
07:30 – 8:45   Each presentation is scheduled for 7 minutes
     
  OP–01 HPV and Bladder Cancer: A New Challenge for the Urological Research
    Sandra Mazzoli
     
  OP-03 Prognostics Relevance of the Detection of HPV High Risk DNA Types 16, 16 & 45 Using the QIAGEN HPV 16/18/45 Probe Set in HPV High Risk Positive Specimens: First Result
    Sven Tiews
     
  OP-04 New High-throughput Method for Oncogenic Human Papillomaviruses genotyping by multiplex Fluorescent PCR (f-HVP typing) in 4051 cervical samples
    Paz Cañadas
     
  OP-05 HPV Infections among Adolescent Population and High School Rock Concerts for Education of Humanpapillomaviruses
    Dubravko Lepusic
   
  OP-06 Combined HPV Genotyping and Cell-Based E6, E7 mRNA (HPV OncoTect) Detection in Cervical Cytology Specimens Performed on a Molecular Hybrid Platform (MoHP) Maximizes Sensitivity and Positive Predictive
  Bruce Patterson
     
  OP-07 Evaluation of 16,18,45 HPV DNA Probe – Comparation with Cervical Cytology and Follow Up
    Danijela Vrdoljak-Mozetič
     
  OP-08 Conjunctive Use of the Cervatec p16 ELISA Significantly Increases the Sensitivity for Detection of CIN2+ Over Conventional Pap Cytology Alone - Results from a Prospective Screening Trial
    Petra Klement
     
  OP-09 HPV E6, E7 mRNA Expression in Ectocervical Cells (HPV OncoTect) Predicts Disease Progression in Women with Low Grade Intraepithelial Neoplasia (LSIL)
    Francisco Alameda
     
08:45 – 09:00   MORNING COFFEE
     
09:00 – 09:15   HPV in Cervical Cancer Research Grant
    Chris Meijer, Joakim Dillner
     
    Chair: Ethel-Michele de Villiers
   
09:15 -  09:45   Epidemiology of HPV infection
    Gary Clifford
   
09:45 – 10:15   Immunology of HPV
    Sjoerd van der Burg
   
10:15 – 10:45   HPV Infection in Women
    Lukáš Rob
   
10:45 – 11:05   COFFEE BREAK
     
    Chair:  Šárka Němečková
     
11:05 – 11:35   HPV Prevalance and Type Distribution in Ano-genital Cancers other than Cervical Cancer
    Silvia Franceschi
     
11:35 – 11:55   HPV Infection and Head and Neck Diseases
    Ruth Tachezy, Jan Klozar
     
11:55 – 12:15   Development of Clinically Effective Therapeutic HPV Vaccines
    Sjoerd van der Burg
     
12:15 – 12:30   LUNCH BREAK
     
12:30 – 14:00   MSD Satellite Symposium in "HPV in Human Pathology Congress"
    Primary Cervical Cancer Prevention and Beyond
     
    Chairman: Prof. MUDr. Roman Prymula, CSc., Ph.D.
     
    Need for collaborative effort
    Prof. MUDr. Roman Prymula, CSc., Ph.D.
     
    Underlining the clinical efficacy - Sustained protection by a Quadrivalent HPV vaccine
    Prof. Ole-Erik Iversen, MD, Phd
     
    Global approach: recommendations & guidelines
    Prof. MUDr. Roman Prymula, CSc., Ph.D.
     
     
    Chair: Marc Van Ranst
     
14:00 – 14:30   HPV DNA Detection
    Peter J. F. Snijders
     
14:30 – 15:00   Detection of HPV Specific Antibodies
    Michael Pawlita
     
15:00 – 15:30   Standards, Quality Assurance
    Lena Dillner
     
15:30 – 15:50   COFFEE BREAK
     
    Chair: Jaroslava Dušková
     
15:50 – 16:20   Liquid compared with Conventional Cervical Cytology
    Christine Bergeron
     
16:20 – 16:50   LBC in UK Screening
    Amanda Herbert
     
16:50 – 17:20   Cyto and HPV in Finland
    Ahti Anttila
     
17:20 – 17:40   COFFEE BREAK
     
17:40 – 18:25   Pro X Con, Cyto, HPV, Both
    Christine Bergeron, Chris Meijer, Joakim Dillner
    Each presentation - 15 minutes, discussion

 

Saturday, May 3, 2008

    Chair: Jan Klozar
     
07:30 – 8:45   Each presentation is scheduled for 7 minutes
     
  OP-10 HPV Infection in Mothers of Children with Recurrent Respiratory Papillomatosis
    Nathalia Babkina
     
  OP-11 Comparison of Clinical Potential of Vaccine-related Types (16-18) and Other HR-HPV Types in Follow-Up of Women with Squamous Intraepithelial Lesions of the Uterine Cervix
    Carmine Carriero
     
  OP-12 Exposure of HPV31b Infected Keratinocytes to Cigarette Smoke Carcinogen Benzo[a]pyrene Results in Alteration of Host Cell Cycle Profile and Viral Life Cycle
    Craig Meyers
     
  OP-13 Does the Easy-to-make Penile Lesions Detection Test Help Us in Routine Diagnosis of High-Risk Human Papillomavirus Types (hrHPV)in Men?
    Vitaly Smelov
     
  OP-14 Effect of HPV on Treatment Outcome and Survival in Oropharyngeal Carcinoma - a Subgroup Analysis of the Randomized DAHANCA 5&7 Trials
    Pernille Lassen
     
  OP-15 Is HPV Vaccination Cost-Effective in the Dutch Situation?
    Inge de Kok
     
  OP-16 Native Versus Synthetic Papillomavirus Particles
    Craig Meyers
     
  OP-17 High-Risk Human Papillomavirus Screened on 1,686 Italian Patients: Epidemiological, Clinical and Vaccinal Implications
    Sandra Mazzoli
     
  OP-18 A Comparison of Performance Parameters for Cervical Cancer Screening in European Countries
    Guglielmo Ronco
     
08:45 – 09:00   MORNING COFFEE
     
    Chair: Marc Arbyn
     
09:00 – 09:15   Screening - Introduction
    Marc Arbyn
     
09:15 – 10:15   The EU 15
    Finland, France, Sweden, Holland, UK (5x10 min)
    Ahti Anttila, Christine Bergeron, Joakim Dillner, Chris Meijer, Amanda Herbert
    Discussion
     
10:15 – 10:45   COFFEE BREAK
     
10:45 – 11:45   The New EU & Candidate Countries
    Poland, Czech Republic, Croatia, Slovakia, Slovenia (5x10 min)
    Marek Spaczynski, Ruth Tachezy, Magdalena Grce, Helena Hupková, Maja Zakelj
    Discussion
     
11:45 – 12:00   Screening - Conclusions
    Marc Arbyn
     
12:00 – 13:00   LUNCH BREAK
     
    Chair: Philips Davies
     
13:00 – 13:30   HPV Awareness and Education
     
13:00 – 13:10   Awareness of HPV and Cervical Cancer in Europe
    Philip Davies
     
13:10 – 13:20   WHO Europe – Programmes to Raise Awareness of Cervical Cancer Prevention
    Gunta Lazdane
     
13:20 – 13:30   Awareness and Education in the Czech Republic
    Jana Petrenko
     
13:30 – 14:30   Vaccines – Controversaries
     
13:30 – 13:45   Vaccination of Infected Women and HPV Typing before Vaccination
    Ole-Erik Iversen
     
13:45 – 14:00   Vaccination of Men
    Joakim Dillner
     
14:00 – 14:15   Benefit of vaccination for other HPV related diseasses
    Gary Clifford
     
14:15 – 14:30   Discussion
     
14:30 – 16:00   SESSION I.
    Gynecology Clinic
    Lukáš Rob, Charles W.E. Redman, Joseph Jordan
     
14:30 – 14:50   European Guidelines – Management of Abnormal Cytology
    Joseph Jordan
     
14:50 – 15:10   Guidelines for the Management of the Precancerous Lesions
    Charles Redman
     
15:10 – 15:30   Less Radical Fertility Sparing Surgery than Radical Trachelectomy in Early Cervical Cancer
    Marek Pluta
   
15:30 – 15:40 OP-19 DNA HR HPV in Cervical Cancer Tissue, in Sentinel and Other Pelvic Lymph Nodes - a Correlation with Histopathological and Imunohistochemical Results
    Jiří Sláma
     
15:40 – 15:50   HPV Profile for Vulvar Leasions
    Petr Škapa
     
15:50 – 16:00   Discussion
   
14.30 – 16.00   SESSION II.
    Head and Neck
    Jan Klozar, Stina Syrjanen, Lalle Hammarstedt, Kateřina Lehovcová, Ruth Tachezy
     
14.30 – 14.50   Natural history of oral HPV infection-what do we know
    Stina Syrjanen
     
14.50 – 15.05   Recurrent respiratory papillomatosis in children age
    Kateřina Lehovcová
     
15.05 – 15.20   Tonsillar cancer: incidence, prevalence of HPV and survival
    Lalle Hammarstedt
     
15.20 – 15.30   The role of HPV as risk and prognostic factor in HNSCC
    Jan Klozar
     
15.30 – 15.40   The methods of selection of patients at risk of HPV associated head and neck tumors
    Ruth Tachezy
     
15.40 – 16.00   Discussion
     
     

 

 -